These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9597051)

  • 1. Preferences of elderly men for prostate-specific antigen screening and the impact of informed consent.
    Wolf AM; Schorling JB
    J Gerontol A Biol Sci Med Sci; 1998 May; 53(3):M195-200. PubMed ID: 9597051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of interest in prostate-specific antigen screening and the impact of informed consent: what should we tell our patients?
    Wolf AM; Philbrick JT; Schorling JB
    Am J Med; 1997 Oct; 103(4):308-14. PubMed ID: 9382123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of informed consent on patient interest in prostate-specific antigen screening.
    Wolf AM; Nasser JF; Wolf AM; Schorling JB
    Arch Intern Med; 1996 Jun; 156(12):1333-6. PubMed ID: 8651843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of patient preference in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team.
    Flood AB; Wennberg JE; Nease RF; Fowler FJ; Ding J; Hynes LM
    J Gen Intern Med; 1996 Jun; 11(6):342-9. PubMed ID: 8803740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What should men know about prostate-specific antigen screening before giving informed consent?
    Chan EC; Sulmasy DP
    Am J Med; 1998 Oct; 105(4):266-74. PubMed ID: 9809686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested.
    Watson E; Hewitson P; Brett J; Bukach C; Evans R; Edwards A; Elwyn G; Cargill A; Austoker J
    Patient Educ Couns; 2006 Nov; 63(3):367-79. PubMed ID: 16875796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Informed decision making on PSA testing for the detection of prostate cancer: an evaluation of a leaflet with risk indicator.
    van Vugt HA; Roobol MJ; Venderbos LD; Joosten-van Zwanenburg E; Essink-Bot ML; Steyerberg EW; Bangma CH; Korfage IJ
    Eur J Cancer; 2010 Feb; 46(3):669-77. PubMed ID: 20022239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions?
    O'Dell KJ; Volk RJ; Cass AR; Spann SJ
    J Fam Pract; 1999 Sep; 48(9):682-8. PubMed ID: 10498074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does evidence-based information about screening for prostate cancer enhance consumer decision-making? A randomised controlled trial.
    Gattellari M; Ward JE
    J Med Screen; 2003; 10(1):27-39. PubMed ID: 12790313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uninformed consent: mass screening for prostate cancer.
    Justman S
    Bioethics; 2012 Mar; 26(3):143-8. PubMed ID: 20497167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deliberative democracy and cancer screening consent: a randomised control trial of the effect of a community jury on men's knowledge about and intentions to participate in PSA screening.
    Thomas R; Glasziou P; Rychetnik L; Mackenzie G; Gardiner R; Doust J
    BMJ Open; 2014 Dec; 4(12):e005691. PubMed ID: 25539779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors of prostate cancer screening among health fair participants.
    Chiu BC; Anderson JR; Corbin D
    Public Health; 2005 Aug; 119(8):686-93. PubMed ID: 15949522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment.
    Howard K; Salkeld GP; Patel MI; Mann GJ; Pignone MP
    Health Expect; 2015 Dec; 18(6):3123-35. PubMed ID: 25382490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PSA screening among elderly men with limited life expectancies.
    Walter LC; Bertenthal D; Lindquist K; Konety BR
    JAMA; 2006 Nov; 296(19):2336-42. PubMed ID: 17105796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Informed consent for cancer screening with prostate-specific antigen: how well are men getting the message?
    Chan EC; Vernon SW; O'Donnell FT; Ahn C; Greisinger A; Aga DW
    Am J Public Health; 2003 May; 93(5):779-85. PubMed ID: 12721144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of an Educational Program for Prostate Cancer Prevention on knowledge and PSA Testing in Men Over 50 Years old in Community Areas of Shiraz in 2016.
    Molazem Z; Ebadi M; Khademian M; Zare R
    Asian Pac J Cancer Prev; 2018 Mar; 19(3):633-637. PubMed ID: 29580031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial of shared decision making for prostate cancer screening.
    Volk RJ; Cass AR; Spann SJ
    Arch Fam Med; 1999; 8(4):333-40. PubMed ID: 10418541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A community-based intervention to promote informed decision making for prostate cancer screening among Hispanic American men changed knowledge and role preferences: a cluster RCT.
    Chan EC; McFall SL; Byrd TL; Mullen PD; Volk RJ; Ureda J; Calderon-Mora J; Morales P; Valdes A; Kay Bartholomew L
    Patient Educ Couns; 2011 Aug; 84(2):e44-51. PubMed ID: 21237611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
    Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
    Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Informed consent for PSA testing.
    Brown V
    J Fam Pract; 1996 Sep; 43(3):234-5. PubMed ID: 8797747
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.